Full-Time

Director of Business Development

Deadline 2/24/27
WuXi AppTec

WuXi AppTec

1,001-5,000 employees

Global contract research, development, manufacturing organization

No salary listed

Remote in USA

Remote

Remote in the United States.

Category
Business & Strategy (1)
Required Skills
Lead Generation

Get referred to WuXi AppTec

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Chemistry with 7+ years of industrial experience and 3+ years of business development experience
  • Experience in Contract Research Organization (CRO) is a plus/preferred
  • Demonstrates a broad understanding of discovery leading to candidate selection through preclinical development, with early phase Chemistry, Manufacturing, and Controls (CMC) knowledge a plus
  • Demonstrates the ability to be a self-starter and to function in a self-motivated and highly flexible manner
  • Able to work independently and must be organized and detail-oriented
  • Proven experience in creating or capitalizing on opportunities leading to successful outcomes, ideally with Business Development relevance, and the ability to analyze situations or data with multiple factors
  • Independently identifies potential prospects and coordinates with other business development and scientific counterparts to provide appropriate solutions to clients; marketing to ensure coordination of efforts and good communication with all parties
  • Interpersonal skill sets for effective listening, dialogue and interactions
Responsibilities
  • Identify potential business prospects (leads) in region across pharma, biotech, VC, non-profits, research institutes, agricultural, and veterinary sciences
  • Identify key decision makers relative to the Research Chemistry Service (RCS) business for potential contact and collaboration
  • Qualify leads and present opportunity(ies) to the technical team and Research Chemistry Services senior leadership
  • Facilitate business meetings with proper agenda, attendees, focus on opportunity, and follow-up; meeting summary Research Chemistry Services as a solutions provider with clearly articulated messages
  • Support proposal writing with the technical team, with an emphasis on consistency, quality of proposal, and presentation of proposal to the customer
  • Support proposal negotiations and strong closing skillset required
  • Point of contact for Research Chemistry Services and customers; ensure communication channels; pro-actively identify areas of growth opportunity; ensure stable relationships, identify issues which could jeopardize partnership; pose solutions
  • Effective representation of Research Chemistry Services at various meetings/conferences; event planning and execution
  • Provide advice and solutions on complex matters using in-depth professional knowledge, acumen, concepts, and models in creative and effective ways
  • Identify and network with stakeholders, including key contacts outside one's own area of expertise. Maintain excellent relationships with internal business partners at WuXi
  • Facilitate and support customer travel to China

What WuXi AppTec does: It provides a global, integrated open-access platform for contract research, development, and manufacturing services (CRDMO) to the pharmaceutical, biotechnology, and medical device industries. How its products work: Clients access a broad portfolio of capabilities—laboratory testing, process development, and manufacturing—across the full product lifecycle, from discovery and preclinical work to clinical and commercial production, often supported by strategic acquisitions to extend reach. How it differs from competitors: It combines extensive geographic reach with a wide, end-to-end service portfolio in one platform, rather than focusing on a narrow stage or region. What its goal is: To help innovators bring new medicines and healthcare products to market faster and with high quality.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Huangpu, China

Founded

2000

Get referred to WuXi AppTec

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • WuXi TIDES capacity expansion targets complex modality demand.
  • Taixing and Singapore plants diversify global manufacturing footprint.
  • Automated compound management improves traceability and reduces workflow friction.

What critics are saying

  • U.S. procurement restrictions can rapidly cut off major biopharma accounts.
  • 2027-2028 plant timing risks missing near-term peptide demand.
  • Robotics and data-integrity failures could disrupt regulated compound handling.

What makes WuXi AppTec unique

  • Integrated CRDMO spans discovery, development, and manufacturing globally.
  • Founded in 2000 by Ge Li in Shanghai.
  • 2008 AppTec acquisition broadened North American capabilities.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
WuXi AppTec reports record $6.2B revenue, 41.3% profit surge in 2025

WuXi AppTec, a global pharmaceutical contract research, development and manufacturing organisation, reported record 2025 results, beating full-year guidance. Total revenue reached RMB 45.46 billion, up 15.8% year-on-year, whilst revenue from continuing operations rose 21.4% to RMB 43.42 billion. Adjusted non-IFRS net profit increased 41.3% to RMB 14.96 billion, with the profit margin rising 5.9 percentage points to 32.9%. The company's backlog for continuing operations grew 28.8% to RMB 58.00 billion. The firm added 839 new molecules to its small molecule development and manufacturing pipeline in 2025, bringing the total to 3,452. WuXi AppTec achieved its first MSCI AAA and CDP Climate Change A ratings during the year.

EIN Presswire
Dec 17th, 2025
Yale and Princeton-funded Chinese firm buys stake in Shanghai biotech linked to military

A Chinese investment firm funded by Yale and Princeton universities has purchased a stake in WuXi AppTec, a Shanghai biotech company that US lawmakers say operates genetic testing centres in coordination with China's People's Liberation Army. The company has faced accusations of assisting Beijing in identifying Uyghur Muslims in Xinjiang. Last year, American legislators warned about WuXi AppTec's military connections and operations. The investment highlights concerns about elite US institutions indirectly funding Chinese companies with military ties through their endowment investments. Neither the investment firm nor the universities have publicly commented on the transaction or its implications for national security.

PR Newswire
Dec 10th, 2025
D3 Bio raises $108M Series B to advance global Phase III trials for cancer drug elisrasib

D3 Bio, a clinical-stage biotechnology company focused on oncology therapeutics, has raised $108 million in a Series B financing round. The round was backed by IDG Capital and SongQing Capital, with participation from existing investors including WuXi AppTec's Corporate Venture Fund, Temasek, HSG, MPCi and Medicxi. The funding will primarily support D3 Bio's planned global Phase III pivotal programme for elisrasib (D3S-001), its lead asset targeting KRAS G12C-mutant cancers. The trials will evaluate elisrasib as monotherapy and in combination treatments across the United States, China and the European Union to facilitate global regulatory submissions. The proceeds will also advance D3 Bio's pipeline of targeted and immuno-oncology programmes with first-in-class or best-in-class potential.

PR Newswire
Apr 1st, 2025
Wuxi Apptec'S Changzhou And Taixing Api Sites Successfully Pass Fda Inspections

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of RD and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec's unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide

intelligence360
Feb 17th, 2025
Wuxi Apptec To Spend $510 Million To Occupy 1.74 Million Square Feet Of Space In Middletown Delaware.

WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware. WuXi AppTec to spend $510 Million to occupy 1.74 Million square feet of space in Middletown Delaware.Middletown, Delaware — According to state and local development sources, WuXi AppTec plans to invest $510,000,000.00 to build out 1,740,000 square feet of new space in Middletown. The company plans to occupy the new space in Middletown, on or about August 1, 2026. According to the company website As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of RD and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTecs integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need and to realize the vision that every drug can be made and every disease can be treated.To learn more about WuXi AppTec, visit http://www.wuxiapptec.com/Company Contact:Rick Connell, [email protected]://www.linkedin.com/in/rick-connell/857-413-2800SOURCE: http://www.intelligence360.ioCopyright (c) 2025 SI360 Inc